CCEL · Cryo Cell International Inc
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $31.13M | $31.57M | $31.99M | $31.34M | $30.34M | $28.88M | $31.15M | $31.82M | $29.22M | $25.38M | $23.13M | $21.09M | $20.13M | $18.99M | $17.97M | $17.92M | $17.76M | |
| $6.87M | $7.38M | $7.95M | $8.39M | $8.79M | $8.99M | $9.66M | $10.04M | $8.54M | $6.72M | — | — | — | — | — | — | — | |
| $24.26M | $24.19M | $24.04M | $22.95M | $21.54M | $19.9M | $21.49M | $21.78M | $20.68M | $18.66M | — | — | — | — | — | — | — | |
| — | 76.63% | 75.15% | 73.23% | 71.02% | 68.88% | 68.99% | 68.46% | 70.77% | 73.51% | — | — | — | — | — | — | — | |
| $311.95K | $376.26K | $1.24M | $1.17M | $384.79K | $49.87K | $23.85K | $30.15K | $91.85K | $41.17K | $53.1K | $45.78K | $64.37K | $36.17K | $109.64K | $184.05K | $132.99K | |
| $18.95M | $18.22M | $18.52M | $17.17M | $15.58M | $14.61M | $14.29M | $14.89M | $15.63M | $13.48M | $14.72M | $12.39M | $12.25M | $11.37M | $14.43M | $12.41M | $9.49M | |
| $46K | $58K | $68K | $96K | $96K | $89K | $68K | $92K | $76K | $35K | $44K | $23K | $28K | $394K | $74K | $40K | — | |
| $975.67K | $985.24K | $693.85K | $1.4M | $1.5M | $1.04M | $372.29K | $401.31K | $317.33K | $131.61K | $154.67K | $92.11K | $171.33K | $188.13K | $204.15K | $361.23K | $294.06K | |
| $31.23M | $31.08M | $28.51M | $43.65M | $26.31M | $24.87M | $23.49M | $26.75M | $24.03M | $20.38M | $22.69M | $18.16M | $18.15M | $17.29M | $19.68M | $18.2M | $14.42M | |
| -$103.78K | $482.39K | $3.48M | -$12.3M | $4.02M | $4.02M | $7.66M | $5.06M | $5.19M | $5.01M | $433.59K | $2.93M | $1.98M | $1.7M | -$1.71M | -$276.74K | $3.35M | |
| — | 1.53% | 10.88% | -39.26% | 13.27% | 13.91% | 24.6% | 15.91% | 17.76% | 19.72% | 1.87% | 13.91% | 9.84% | 8.96% | -9.52% | -1.54% | 18.83% | |
| $871.9K | $1.47M | $4.17M | -$10.9M | $5.52M | $5.06M | $8.03M | $5.46M | $5.51M | $5.14M | $588.27K | $3.03M | $2.15M | $1.89M | -$1.51M | $84.49K | $3.64M | |
| $1.92M | $2.07M | $1.86M | $1.24M | $1.52M | $1.38M | $1.54M | $1.7M | $1.55M | $1.3M | $947.34K | $1.3M | $1.15M | $1.4M | $1.02M | $1.46M | $1.28M | |
| $45.63K | — | — | — | — | — | — | — | — | — | — | — | — | — | $63.49K | $36.91K | $26.3K | |
| -$2.44M | -$2.82M | -$676.16K | -$1.06M | -$705.52K | -$1.41M | -$2.62M | -$1.67M | -$1.57M | -$1.38M | -$2.91M | -$1.96M | -$941.2K | -$1.35M | -$2.55M | -$1.42M | -$1.26M | |
| — | — | — | — | — | — | — | — | — | — | — | -$18.82K | -$362.88K | -$154.05K | -$154.56K | -$227.02K | -$183.41K | |
| -$2.55M | -$2.34M | $2.8M | -$13.36M | $3.32M | $2.61M | $5.04M | $3.39M | $3.62M | $3.62M | -$2.48M | $949.52K | $677.15K | $197.02K | -$4.42M | -$1.92M | $1.9M | |
| -$81.55K | $92.23K | $2.4M | -$3.84M | $547.54K | $527.71K | $1.41M | $1.1M | $4.47M | $1.31M | -$1.16M | -$7.16M | $123.53K | $169.58K | $1.89M | $171.94K | -$1.56M | |
| -$2.47M | -$2.43M | $402.1K | -$9.52M | $2.77M | $2.08M | $3.62M | $2.29M | -$854.82K | $2.32M | -$1.32M | $8.11M | $553.62K | $27.44K | -$6.31M | -$2.1M | $3.46M | |
| — | -7.7% | 1.26% | -30.38% | 9.14% | 7.21% | 11.64% | 7.2% | -2.93% | 9.12% | -5.71% | 38.43% | 2.75% | 0.14% | -35.11% | -11.69% | 19.5% | |
| — | — | — | — | — | — | — | $2.29M | -$554.71K | $2.32M | -$1.46M | $8.28M | $553.62K | — | — | -$2M | — | |
| USD/shares | — | -$0.30 | $0.05 | -$1.14 | $0.33 | $0.26 | $0.48 | $0.29 | -$0.11 | $0.33 | -$0.16 | $0.85 | $0.05 | $0.00 | -$0.56 | -$0.18 | $0.29 |
| USD/shares | — | -$0.30 | $0.05 | -$1.14 | $0.33 | $0.25 | $0.45 | $0.27 | -$0.11 | $0.30 | -$0.16 | $0.83 | $0.05 | $0.00 | -$0.56 | -$0.18 | $0.29 |
| shares | — | 8.07M | 8.13M | 8.34M | 8.47M | 8.14M | 7.54M | 7.79M | 7.46M | 7.06M | 8.11M | 9.54M | 10.18M | 10.86M | 11.31M | 11.76M | 11.75M |
| shares | — | 8.07M | 8.21M | 8.34M | 8.48M | 8.36M | 8.14M | 8.41M | 7.46M | 7.65M | 8.11M | 9.8M | 10.43M | 10.97M | 11.31M | 11.76M | 11.81M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2012–FY2025: $25.03M in buybacks, $12.92M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 16 similar-size Medical Care Facilities companies (of 57 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Umbilical Cord Blood and Cord Tissue Stem Cell Service | $31,382,704 | $31,551,550 | $30,796,091 | $29,771,123 | $28,397,401 | $30,176,852 |
| Public Cord Blood Banking | $129,513 | $366,672 | $481,148 | $461,626 | $376,101 | $726,554 |
| Prepacyte CB | $54,104 | $67,884 | $66,456 | $104,000 | $111,400 | $244,187 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Processing and Storage Fees | $31,382,704 | $31,551,550 | $30,796,091 | $29,771,123 | $28,397,401 | $29,547,150 |
| Public Banking | $129,513 | $366,672 | $481,148 | $461,626 | $376,101 | $726,554 |
| Product | $54,104 | $67,884 | $66,456 | $104,000 | $111,400 | $244,187 |
| Licensee and Royalty Income Recognition | — | — | — | — | — | $629,702 |
| Processing and Storage Royalties | — | — | — | — | — | $629,702 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Umbilical Cord Blood and Cord Tissue Stem Cell Service | $5,411,691 | $4,131,796 | -$7,911,698 | $5,185,305 | $6,362,172 | $9,928,886 |
| Prepacyte CB | $14,206 | -$4,976 | $3,188 | -$24,493 | -$70,335 | $60,499 |
| Public Cord Blood Banking | -$4,943,503 | -$646,536 | -$4,395,522 | -$1,136,345 | -$2,273,604 | -$2,327,788 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Umbilical Cord Blood and Cord Tissue Stem Cell Service | 17.2% | 13.1% | -25.7% | 17.4% | 22.4% | 32.9% |
| Public Cord Blood Banking | -3817% | -176.3% | -913.5% | -246.2% | -604.5% | -320.4% |
| Prepacyte CB | 26.3% | -7.3% | 4.8% | -23.6% | -63.1% | 24.8% |